Drug Executive Collapses During Oval Office Event
A drug executive fainted in the Oval Office as President Donald Trump announced an agreement with pharmaceutical companies to lower obesity drug prices.
Incident Details
The press conference was abruptly interrupted when Gordon Findlay, Novo Nordisk's global brand director, collapsed during remarks by Eli Lilly's CEO, David Ricks.
"Are you okay? Gordon, are you okay?" asked David Ricks after noticing the executive in distress.
Immediate Response
Dr. Mehmet Oz, Administrator for the Centers for Medicare & Medicaid Services, quickly assisted Findlay as he fell to his knees and lost consciousness. Health and Human Services Secretary was also present at the scene.
The press was promptly escorted out of the room following the incident.
Event Resumption and Follow-up
About 30 minutes later, the press conference resumed, and President Trump provided an update on Findlay's condition.
Context of the Announcement
Trump and drugmakers Eli Lilly and Novo Nordisk were discussing expanding coverage and reducing the prices of popular obesity treatments, Zepbound and Wegovy.
"Trump and drugmakers were speaking to the press regarding a deal with Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy."
Summary
This unexpected health emergency briefly disrupted a significant event focused on making obesity drugs more accessible and affordable.
Author's summary: A sudden collapse of a Novo Nordisk executive interrupted President Trump's press conference on affordable obesity drug deals, highlighting the unpredictability of live events.